Press Room
Your source for Genoskin news, insights, & milestones
Genoskin is redefining drug development with donated human skin samples
that are kept alive to generate real human data
Our proprietary technologies, including the cutting-edge ImmunoSafe ISR platform, help pharmaceutical and biotech innovators predict human safety and efficacy earlier—reducing costly late-stage failures. By reducing reliance on animal models with clinically relevant human insights, we accelerate R&D, unlock new therapeutic possibilities, and position our partners at the forefront of safer, faster, and more ethical drug discovery.
The entire Genoskin team follows strict regulatory guidelines to comply with all applicable ethical and quality regulations. All Genoskin procedures and processes are ISO9001-certified.
Genoskin at a glance: Key figures & global footprint
Corporate news & media coverage
Media coverage: Browse through a selection of press coverage highlighting Genoskin’s philosophy
Benzinga
Genoskin offers live skin models to bridge animal, human testing: ‘The market opportunity is huge’
Boston Business Journal
This Salem biotech uses live human skin to test drugs and cosmetics
Drug discovery & development
Inside Genoskin’s quest to use human skin scraps to accelerate drug research
BioSpace
Human skin replaces some animal testing, expedites drug development
Press releases: Genoskin’s latest announcements
Insights from our blog: Innovation and research updates
Our leadership: Meet Genoskin’s executive team
Pascal Descargues, PhD
Founder, CEO
Frederik Roques
Chief Financial Officer
Vicky Tourte
HR & Administrative Director
Nicolas Gaudenzio, PhD
Chief Scientific Officer
Anna Falkovsky
Vice President of Sales
Lorna Santos, PhD
Vice President of Research & Product Development
Media kit & brand assets
Peer-reviewed scientific publications & research presentations
Peer-reviewed publications
Discover how Genoskin’s ex vivo human skin models advance drug development, backed by leading scientific research.
- Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA-1273 COVID-19 vaccine.
Allergy – August 2024
Manon Scholaert, Mathias Peries, Emilie Braun, Jeremy Martin, Nadine Serhan, Alexia Loste, Audrey Bruner, Lilian Basso, Benoît Chaput, Eric Merle, Pascal Descargues, Emeline Pagès, Nicolas Gaudenzio. - 3D deconvolution of human immune architecture with Multiplex Annotated Tissue Imaging System
Science Advances – June 2023
Manon Scolaert, Raissa Houmadi, Jeremy Martin, Nadine Serhan, Marie Tauber, Emilie Braun, Lilian Basso, Eric Merle, Pascal Descargues, Manuelle Viguier, Cécile Lesort, Benoît Chaput, Jean Kanitakis, Denis Jullien, Cristina Bulai Livideanu, Laurence Lamant, Emeline Pagès, Nicolas Gaudenzio.
- Development and characterization of a human Th17-driven ex vivo skin inflammation model
Experimental Dermatology – October 2020
Claire Jardet, Anthony David, Emilie Braun, Pascal Descargues, Jean-Louis Grolleau, Josephine Hebsgaard, Hanne Norsgaard, Paola Lovato.
Conference talks & poster presentations
Genoskin periodically shares its latest research at major international scientific conferences.
- Optimizing vaccine candidate selection: an insight into VaxSkin’s human skin-based multimodal immune profiling platform.
Tech Talk, World Vaccine Congress Europe – October 2023
Nicolas Gaudenzio - Mitigation of Injection Site Reactions after Subcutaneous Administration of Dalcinonacog Alfa (DalcA) in Hemophilia B Using Preclinical Models.
Poster presentation, ISTH Congress – July 2021, Abstract PB0453
Natacha Le Moan, Lauren Kelly, Eric Merle, Pascal Descargues, Nicolas Gaudenzio, Hugo Gagnon, Anju Chatterji, Grant E. Blouse.
Upcoming events, webinars & global conferences
Stay connected with Genoskin’s scientific community presence
Our experts regularly present at leading international conferences, share insights during webinars, and contribute to panel discussions that shape the future of drug development and skin research.
- Genoskin Webinar Series: Drug-specific antibody repertoires from allergics: a source of therapeutics?
September 10, 2025 – Online
Live webinar with Q&A hosted by Dr. Nicolas Gaudenzio, featuring Dr. Pierre Bruhns
- 2026 SOT Annual Meeting and ToxExpo
March 22-25, 2026 – San Diego, California, USA
Awards, Certifications & Industry Recognition
Genoskin’s innovative spirit, scientific excellence, and sustained growth have been honored by prestigious organizations in France and internationally.
- Growth Champions list – Statista – 2024
- Occitanie Invest Laureate – Ad’Occ & La Région Occitanie – 2024
- Financial Times Top 1000 of Fastest Growing European Companies – 2022 & 2023
- Scale Up Excellence Program Laureate – French Tech Toulouse – 2021
- NETVA (New Technology Venture Accelerator) Award – Science & Technology Department, Embassy of France in the United States – 2016
- ISO9001 Certification – Demonstrating commitment to quality and continuous improvement – 2015
- Innovation Award – French Entrepreneurship Network (Réseau Entreprendre) – 2012
- Innovative Company Award – French Ministry of Higher Education & Research and the French Agency for Innovation OSEO (now BPI France) – 2010 & 2011
